Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trialYoung‐Suk Lim, Seungbong Han, Won‐Mook Choi et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 23
Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and ThailandSiwaporn Chainuvati, Xin Xin Zhang, Jun Cheng et al.|Hepatology International|2009Cited by 9